Receive our newsletter – data, insights and analysis delivered to you
  1. News
November 15, 2017updated 26 Nov 2021 4:19am

Akcea launches Phase II programme for rare hyperlipidemias

US-based Ionis Pharmaceuticals’ affiliate Akcea Therapeutics has launched a Phase II clinical programme of AKCEA-ANGPTL3-L to treat rare hyperlipidemias.

US-based Ionis Pharmaceuticals’ affiliate Akcea Therapeutics has launched a Phase II clinical programme of AKCEA-ANGPTL3-L to treat rare hyperlipidemias.

AKCEA-ANGPTL3-L ­is being developed to minimise the production of angiopoietin-like 3 (ANGPTL3) for cardioprotective effect and decreased risk of insulin resistance and diabetes mellitus.

The Phase II programme will include three clinical trials for familial chylomicronemia syndrome (FCS), familial partial lipodystrophy (FPL), and homozygous familial hypercholesterolemia (HoFH).

In addition to evaluating safety, tolerability, pharmacokinetics, and pharmacodynamics, the trials will aim to characterise the potential of AKCEA-ANGPTL3-L in specific patient populations.

“We are committed to developing additional therapeutic options for these patient populations whose significant medical needs are currently greatly underserved.”

Akcea Therapeutics chief medical officer Louis O’Dea said: “ANGPTL3 is a key regulator of a number of lipid and metabolic pathways and as such is an important target for the therapeutic management of rare hyperlipidemias, such as FCS, FPL, and HoFH.

“We are committed to developing additional therapeutic options for these patient populations whose significant medical needs are currently greatly underserved.”

Content from our partners
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide
Why Asia-Pacific is the next frontier for decentralized clinical trials

The first trial under the programme will include an assessment of subcutaneous, once weekly injection of AKCEA-ANGPTL3-L over a period of 13 weeks in subjects with FCS.

Scheduled to report top-line results next year, this trial will be followed by studies in FPL and HoFH patients.

AKCEA-ANGPTL3-L was found to be well-tolerated during a Phase I/II clinical trial conducted in subjects with increased triglycerides, with an 85% dose-dependent decrease in ANGPTL3 protein after six weeks.

Performed for various doses of the drug candidate, the trial further showed similar reductions in triglycerides; low-density lipoprotein (LDL), very low-density lipoprotein (VLDL), and non-high desnsity lipoprotein (HDL) cholesterol; apolipoprotein B; and apolipoprotein C-III protein.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU